Cancer Drug Trials Show Improved Survival Rates for Genmab, AstraZeneca and Amgen
Late-stage trials demonstrate significant survival benefits for patients using experimental treatments from Genmab, AstraZeneca, and Amgen.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 5 articles since 24 Oct 2026. Bloomberg.com published first, on 24 October at 14:30 UTC; Quartz followed 45h 26m later. The most recent article, from Quartz, appeared on 26 October at 12:36 UTC.
Outlets reporting it: Bloomberg Markets (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- Bloomberg.comAmgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer
- Bloomberg.comAstra’s Experimental Stomach Cancer Drug Doubled Survival Time
- Bloomberg MarketsGenmab Soars as Cancer Drug Impresses in a Late-Stage Trial
- QuartzAstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win
- QuartzAmgen's cancer drug combo cut death risk by 58% in lung cancer trial
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial Bloomberg Markets ·
- Astra’s Experimental Stomach Cancer Drug Doubled Survival Time Bloomberg.com ·
- Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer Bloomberg.com ·
- Amgen's cancer drug combo cut death risk by 58% in lung cancer trial Quartz
- AstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win Quartz
In this story
- Genmab
- AstraZeneca
- Amgen